Clements et al. (48) revealed that BRCA2-deficient cells are less sensitive to PARP inhibitor and cisplatin treatment after E2F7 depletion, thereby indicating that E2F7 could be a putative biomarker for tumor response to PARP inhibitor therapy. The gene discussed is BRCA2; the disease is neoplasm.